Liquid biopsies and the advent of blood-based diagnostics have emerged in recent years as promising alternatives and complements to tissue-based genomic and proteomic assays. Biodesix, a global leader in molecular diagnostics and assay design/development, leverages cutting-edge technology, including droplet digital PCR (ddPCR), to advance translational and clinical oncology research and to assist biopharma companies in delivering new, targeted, life-saving therapies to patients.
This presentation provides a comprehensive exploration of new blood-based diagnostics, including the development of a microsatellite instability (MSI) test on the ddPCR platform and the dynamic monitoring capabilities of ddPCR using circulating tumor DNA (ctDNA).
During this talk we discuss:
- Biodesix assays and their broad applications in cancer research and therapeutic development
- Dynamic monitoring of treatment response using ddPCR detection of ctDNA with insights from a recent biopharma collaboration
